Quarterly ResultAug 3, 2026, 04:13 PM
Twist Bioscience Q3 Revenue Up 23% to $118.4M; Net Loss $(35.1)M
AI Summary
Twist Bioscience reported a 23.23% increase in third-quarter revenue to $118.4 million, but recorded a net loss of $35.1 million, a significant decline from a net income of $20.4 million in the prior year. For the nine months, net loss widened to $109.6 million. The company also announced an asset acquisition and equity investment in Invenra Inc. for its B-Body bispecific antibody discovery platform.
Key Highlights
- Q3 2026 revenue increased 23.23% to $118.4 million from $96.1 million year-over-year.
- Q3 2026 net loss was $(35.1) million, compared to net income of $20.4 million in Q3 2025.
- Basic net loss per share for Q3 2026 was $(0.56), down from $0.34 income per share in Q3 2025.
- Nine-month net loss widened to $(109.6) million from $(50.5) million in the prior year.
- Acquired a license to Invenra's B-Body platform for $20.0 million, including $5.0 million cash.
- Made a $13.8 million equity investment in Invenra Inc.
- Cash and cash equivalents decreased to $117.4 million as of June 30, 2026, from $183.0 million.
- DNA synthesis and protein solutions revenue grew to $56.6 million in Q3 2026.
Price Impact
More from TWST